Your session is about to expire
← Back to Search
HOBSCOTCH Program for Epilepsy
Study Summary
This trial is testing whether a home-based self-management program (HOBSCOTCH) can improve quality of life and perceived difficulties in cognitive abilities. The study will also test a new mobile application and extra booster sessions to improve long-term outcomes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have trouble seeing well enough to read or write.You have reported problems with your memory.I have never been diagnosed with epilepsy.My epilepsy or depression medication hasn't changed in the last month.I have epilepsy with seizures that may or may not be under control.You have been diagnosed with a memory-related illness like dementia.
- Group 1: HOBSCOTCH group
- Group 2: Wait-listed control
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the aggregate number of participants in this trial?
"Affirmative. This clinical trial, which was first listed on March 17th 2021, is actively seeking participants and can be found in the directory of clinicaltrials.gov. 150 patients are necessary to complete this study at one medical centre."
Are any slots available for participation in this experimentation?
"According to the clinicaltrials.gov website, this medical experiment is actively seeking participants. It was launched on March 17th 2021 and its content has been modified most recently on April 14th 2022."
What will be the ultimate outcome of this research endeavor?
"This clinical trial spans across Baseline, Months 3, 6, 9 and 12. The primary outcome to be measured is the Change in Quality of Life in Epilepsy (QOLIE-31) Score. Secondary objectives include tracking changes in Adult Epilepsy Self-Management Measurement Instrument (AESMMI-65), Medication Adherence Rating Scale (MARS), as well as Patient Health Questionnaire - 9 Depression (PHQ-9)."
Share this study with friends
Copy Link
Messenger